In this episode of the PeptideResearch.us Podcast, hosts Amy Andrews and Todd Collins (AI personas of Peptide Research) examine the glucagon receptor arm of Retatrutide, the investigational triple agonist that adds glucagon receptor activity to the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor pharmacology already established by earlier incretin compounds. The discussion explores why glucagon receptor agonism became a focal point in metabolic research models despite glucagon's long-standing identity as a counter-regulatory, glucose-raising hormone.
The episode details the mechanistic core of hepatic glucagon signaling, highlighting the Glucagon Receptor (GCGR) — a class B G protein-coupled receptor expressed predominantly on hepatocytes — and its cyclic adenosine monophosphate (cAMP) and Protein Kinase A (PKA) second-messenger cascade. The conversation breaks down hepatic glycogenolysis and gluconeogenesis, hepatic fatty acid oxidation and its relationship to hepatic lipid content, glucagon-associated increases in resting energy expenditure, and the glycemic offset provided by concurrent GLP-1 receptor agonism. It also covers oxyntomodulin, the endogenous proglucagon-derived peptide that functions as a naturally occurring dual GLP-1R/GCGR agonist and served as the conceptual precedent for designed co-agonism.
Listeners will gain an understanding of why receptor ratio and signaling balance govern triple agonist design, how preclinical models isolate the glucagon arm from its incretin partners, and how rigorous analytical standards like third-party testing and Certificates of Analysis ensure research integrity.
BECOME AN NRG BIOLABS AFFILIATE Already the person your friends text with peptide questions?
The NRG BioLabs affiliate program gives you your own custom Wholesale Peptides link. Share it with the people already asking. When they order through your link, you earn — and you keep earning every time they reorder. Recurring, not one and done.
Join our exclusive text and email club to receive VIP access to special promotions, limited-time discounts, product launches, and subscriber-only offers.
Here's something that sounds like a mistake. Researchers are studying a new compound. It switches on three different signals in the body, and one of those three is the signal that raises your blood sugar.
SPEAKER_00
It does sound like a mistake.
SPEAKER_02
Somebody put that in there on purpose. Today is the whole show on why.
SPEAKER_00
This is part of our ongoing series on the GLP compounds. Hit follow so the next one lands in your feed automatically.
SPEAKER_02
I'm Amy Andrews, and this is the PeptideResearch.us podcast. Todd Collins is with me. Today we're looking at one piece of a compound called retitrutide, the blood sugar piece. Todd, what does somebody walk away knowing?
SPEAKER_00
What that signal actually does, why researchers wanted it in the mix instead of out of it, and why it only makes sense when it's paired with something else. One note before we start. All peptides discussed in this podcast relate to research use only. Any references to data from animals, cells, or human studies relate exclusively to scientific literature and not to products from NRG biolabs. These compounds are not approved drugs or dietary supplements and are not for human consumption. Nothing in this podcast is medical advice.
SPEAKER_01
Okay. Start me at zero.
SPEAKER_00
Here's the simple version. Your body keeps fuel in storage. Something has to tell it when to open the storage up. That's one signal's entire job. It goes out when fuel in your blood is running low.
SPEAKER_01
Oh, so it's a withdrawal slip. Insulin is the deposit slip, that's the one everybody knows. This is the other half. Money in, money out.
SPEAKER_00
That's exactly it. And that withdrawal signal has a name. Researchers call it glucagon.
SPEAKER_01
Glucagon. Okay, where does it go?
SPEAKER_00
Almost every cell can hear it, but only some cells have the lock it fits. And the liver has far more of those locks than anywhere else. So when glucagon goes out, it's really one organ being spoken to by name.
SPEAKER_02
So the liver is the branch where my account actually lives.
SPEAKER_00
I'm stealing that.
SPEAKER_02
Here's my follow-up though. Does the liver only hand back sugar?
SPEAKER_00
No, and this is the part people miss. The liver holds two kinds of reserve. There's sugar, it keeps on hand, and there's fat. Glucagon tells it to spend both. Same instruction, two different shelves. Lab insight. Here's what that looks like on a bench. Put two compounds side by side. One carries the glucagon signal, one doesn't. Then look at the liver itself. In animal studies, the one carrying glucagon leaves less fat sitting inside the liver. Take that signal out, and most of the difference goes with it.
SPEAKER_02
Wait, so it isn't really a sugar hormone at all?
SPEAKER_00
It's a spending hormone. Sugar is just what it spends first.
SPEAKER_02
Then why isn't it obvious? Why not study glucagon on its own?
SPEAKER_00
Because of the thing you flagged at the top. Push it by itself, and yes, the body opens the reserves and burns more fat for fuel. It also pushes blood sugar up, and that's the one direction this whole field has spent 30 years trying to move away from. On its own, it's a bad trade.
SPEAKER_02
So what makes it a good idea with company?
SPEAKER_00
A second signal. Your gut sends this one out when you eat. It nudges blood sugar the other way, down. Researchers call it GLP1.
SPEAKER_02
So one pushes sugar up, one pulls it down.
SPEAKER_00
Right. The bet is that those two mostly cancel, and when they do, the fuel spending part of glucagon is still there.
SPEAKER_02
Oh, that's a hot air balloon. The burner pushes you up, the vent lets you back down. You're not trying to win with either one. You run both so you can hold steady and actually go somewhere. Level two question. Does canceling out just leave you with nothing?
SPEAKER_00
That's exactly the right worry. It comes down to how hard each signal gets pushed. Lean too far one way and the blood sugar problem wins. Lean too far the other way, and you've built something that only does what GLP1 already did. Getting that balance right is the whole job. Lab Insight. In animal studies, you can watch it happen. Run glucagon on its own, and blood sugar drifts up while the animal burns more energy sitting still. Add the GLP1 signal, and that drift flattens out. The energy part stays. Neither signal is doing anything new, they're editing each other.
SPEAKER_02
Okay, who thought of pairing them? Because that sounds very modern.
SPEAKER_00
This is my favorite part. The body did, a long time before we did. There's a hormone your gut already makes that doesn't do one job. It switches on the GLP1 signal and the glucagon signal, both, at the same time.
SPEAKER_02
Wait, what? The combination already existed?
SPEAKER_00
It already existed. Nobody designed it. It's called oxyantomulin, and that's the hardest word in today's episode. I promise it's the last one.
SPEAKER_02
Oh, I love that. That's inventing a tool, being extremely proud of yourself, and then finding the exact same tool in your grandfather's toolbox with the handle already worn smooth. Level two. If the body makes one, why build one?
SPEAKER_00
Two reasons. The natural one doesn't stick around. Your body takes it apart in minutes. And the balance between its two jobs is whatever biology happened to land on, not what a researcher wants to test. A built molecule lets you hold it steady and turn each part up or down on purpose. That's the difference between watching something and actually studying it.
SPEAKER_01
Did you see that shift happen?
SPEAKER_00
I saw it and I got it wrong. Early on, I sat through a poster on oxyantomulin, and I filed the whole thing under odd, a hormone that couldn't decide what it was. I thought it was messy. The messiness was the blueprint. Ten years on, the field builds molecules to be messy on purpose.
SPEAKER_02
I'll give you the listener version of that. I learned hormones as a cast list. Insulin good, glucagon bad, cortisol, villain. I carried that around for years and never once questioned it. What finally broke it was realizing the body doesn't have villains. It has signals that are right at some moments and wrong at others. And the one I'd written off as the bad guy is sitting in the middle of the most interesting work in the field.
SPEAKER_00
Direction and timing. Nothing in there is good or bad. It's either aimed well or it isn't.
SPEAKER_02
And everything we've described today is a balance, which is exactly why it matters where a compound comes from.
SPEAKER_00
Right. If what you're studying is a balance between three signals, then the one thing you can't afford is doubt about what's in the vial. That's why NRG Biolabs is the foundational partner behind this show. Third-party testing, batch-by-batch paperwork, certificates of analysis, the documents that say what's actually in there. You can see the COAs and view the lab standards at peptidesearch.us.
SPEAKER_02
You can't study a balance you don't trust.
SPEAKER_00
Not honestly.
SPEAKER_02
Let me pull it together. Glucagon is the body's withdrawal slip. It talks mostly to the liver and it tells the liver to spend both shelves, sugar and fat.
SPEAKER_00
Right.
SPEAKER_02
On its own, it drags blood sugar the wrong way so it doesn't get studied alone. Pair it with GLP1 and the sugar effects push against each other while the spending part stays.
SPEAKER_00
That's the bet.
SPEAKER_02
And the body already made a two-job version called oxyentomulin long before anybody thought to build one.
SPEAKER_00
That's a fair summary. Oh, and one last thing that's easy to overlook. We talk about this compound reaching three signals, like the number is the achievement. It isn't. Two of the three were already being reached by things we had. The real departure is that somebody was willing to include a signal the whole field had spent a generation trying to shut down.
SPEAKER_02
Oh, I see. The new part wasn't the molecule, it was permission. If you want to sit with this one slowly, there's a plain English write-up on glucagon and this compound at peptidesearch.us. The peptide research section is where I'd start. And if today's breakdown was useful, follow the show. There are 60 plus episodes in the feed covering nearly every research peptide, and you can work through them at your own pace. If you liked this podcast and want to stay up to date on all the latest peptide research, you can find links to our website, Facebook page, and even our Discord channel in the podcast description below. You can even sign up for our newsletter and get notified every time a new episode rolls out. That's our show. Thanks for thinking out loud with us.
